An observational study in Bone Metastases of a Malignant Tumor and Metastatic Bone Tumor, sponsored by Sichuan Provincial People's Hospital. Completed. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Sichuan Provincial People's Hospital · Observational
Bone metastases are common in patients with advanced cancer and frequently involve the proximal humerus, leading to severe pain and loss of shoulder function. Shoulder arthroplasty is an important surgical option for restoring limb function and relieving pain in these patients. However, elderly patients often have multiple comorbidities, and it remains unclear whether age affects surgical outcomes and prognosis after arthroplasty for proximal humeral metastases.
This retrospective observational study reviewed patients with isolated proximal humeral metastases who underwent shoulder arthroplasty at our institution. Patients were divided into elderly and younger groups based on age, and clinical outcomes were compared between the groups. Evaluated outcomes included operative characteristics, postoperative pain, limb function, complications, survival, recurrence, and quality of life.
The aim of this study is to determine whether age influences prognosis and functional recovery after shoulder arthroplasty for proximal humeral metastases, and to assess the feasibility and effectiveness of this surgical procedure in elderly patients.
This retrospective observational study reviewed patients who underwent proximal humeral hemiarthroplasty (PHH) for solitary metastatic lesions of the proximal humerus at our institution between 2013 and 2021. A total of 53 patients with histopathologically confirmed metastatic bone tumors were included in the analysis. The study population consisted of 25 males and 28 females, with ages ranging from 43 to 82 years.
Patients were divided into two groups according to age: Group A (≥65 years, n = 25) and Group B (\<65 years, n = 28). All metastatic lesions were unilateral and located in the proximal one-third of the humerus without involvement of the scapula.
The most common primary malignancies included breast cancer, lung cancer, renal cell carcinoma, thyroid cancer, prostate cancer, colorectal cancer, hepatocellular carcinoma, gastric cancer, uterine cancer, and cancer of unknown primary origin. Prior resection of the primary tumor had been performed in 22 patients before presentation. Nineteen patients had comorbidities such as diabetes mellitus, hypertension, chronic gastritis, or pulmonary emphysema. Pathological fractures were present in 19 cases.
All patients underwent wide tumor excision followed by proximal humeral hemiarthroplasty using a Malawer type I resection technique. Clinical and surgical data were collected from medical records for subsequent analysis.
322 studies on the registry are indexed under Bone Neoplasms; 81 are open to participants now.
This study's enrollment of 53 is below the median of 75 across 93 observational studies indexed under Bone Neoplasms.
Browse Bone Neoplasms studies →Sichuan Provincial People's Hospital is the lead sponsor of 76 studies on the registry; 43 are open to participants now.
Counted across the registry records on this site, refreshed daily.
This study included adult patients with solitary proximal humeral metastases who underwent proximal humeral hemiarthroplasty at our institution between 2013 and 2021. Both male and female patients were eligible. Patients were divided into two groups based on age (≥65 years and \<65 years) to compare surgical outcomes, functional recovery, complications, and survival. All patients had confirmed metastatic bone tumors, with lesions localized to the proximal humerus and without involvement of the scapula or axillary nerve. Patients with multiple bone metastases or severe comorbidities were excluded.
Presence of pathological fracture or a severe osteolytic lesion at risk of fracture (Mirels score ≥9).
Poor response to radiotherapy according to RECIST 1.1 criteria.
Persistent severe shoulder pain or significant loss of shoulder function.
Estimated life expectancy >3 months at the time of surgery..
Exclusion Criteria:
Metastatic lesions affecting the scapula, axillary nerve, or brachial plexus.
Death during the perioperative period.
Presence of three or more significant comorbidities, such as uncontrolled diabetes, severe cardiopulmonary disease, or chronic renal failure.
Loss to follow-up within 3 months after surgery.
Patients aged 65 years or older with solitary proximal humeral metastases who underwent proximal humeral hemiarthroplasty at our institution.
Procedure: Proximal Humeral Hemiarthroplasty
Patients younger than 65 years with solitary proximal humeral metastases who underwent proximal humeral hemiarthroplasty at our institution.
Procedure: Proximal Humeral Hemiarthroplasty
Patients underwent wide tumor excision followed by proximal humeral hemiarthroplasty. En bloc resection was performed according to tumor-free principles, with preservation of the axillary nerve and deltoid muscle whenever possible. Osteotomy was performed 2-3 cm distal to the tumor margin. A tumor-specific prosthesis was implanted and soft tissues were reconstructed. A Ligament Advanced Reinforcement System (LARS) was used when necessary to improve joint stability.
(ASES) Score
Shoulder Function Assessed by the American Shoulder and Elbow Surgeons (ASES) Score
Time frame: Postoperative follow-up (up to 24 months)
No study locations are listed for this record.
Plan to share: No — Individual participant data will not be shared due to patient privacy concerns and ethical restrictions. The data include sensitive medical information collected from hospital records, and sharing such data could risk identification of patients.
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan Provincial People's Hospital